Skip to main content
. 2021 Jul 10;9(7):799. doi: 10.3390/biomedicines9070799

Table 3.

Clinical trials with targeted therapies in IDH-mutant gliomas.

DNA Methyltransferase (DNMT) Inhibitors
ClinicalTrials.gov Identifier Drug Mechanism of Action Phase Status Announced Results
NCT03922555 ASTX727 DNMT and cytidine deaminase inhibitor Phase I Recruiting
NCT03666559 Azacitidine DNMT1 inhibitor Phase II Recruiting
Poly ADP Ribose Polymerase (PARP) Inhibitors
ClinicalTrials.gov Identifier Drug Mechanism of Action Phase Status
NCT03212274 Olaparib (AZD2281) PARP1/2 inhibitor Phase II Recruiting
NCT03561870 Olaparib PARP1/2 inhibitor Phase II Active,
not recruiting
Immunotherapy
ClinicalTrials.gov Identifier Drug Mechanism of Action Phase Status
NCT02454634 IDH1 peptide vaccine (NOA-16) IDH1 peptide vaccine Phase I Completed Favorable safety profile, high percentage of IDH peptide-specific immune response [107]
NCT02771301 IDH1R132H-DC vaccine IDH1R132H-dendritic cell vaccine Phase I Unknown
NCT03557359 Nivolumab Immune checkpoint inhibitor Phase II Recruiting
NCT03718767 Nivolumab Immune checkpoint inhibitor Phase II Recruiting
NCT03925246 Nivolumab Immune checkpoint inhibitor Phase II Active,
not recruiting